BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ivera Medical Corporation Receives FDA 510(k) Clearance to Market its Curos(TM) Port Protector, an Innovative Medical Device Designed to Reduce Patient Exposure to the Risks of Hospital Acquired Bloodstream Infections


10/28/2008 6:37:48 AM

SAN DIEGO--(BUSINESS WIRE)--Ivera Medical Corporation, a San Diego (CA) based medical device company today announced that it received FDA 510(k) clearance to begin marketing its Curos™ Port Protector, an innovative medical device that decontaminates needleless intravenous (I.V.) access ports, and helps to prevent touch and airborne contamination.

According to a recent study published by the Pennsylvania Health Care Cost Containment Council, the incidence and associated cost of hospital acquired bloodstream infections are increasing at an alarming rate. The Curos Port Protector is designed to reduce patient exposure to the risks of hospital acquired bloodstream infections and help maintain hospital infection control protocols.

“The Curos Port Protector market approval is a significant milestone toward the success of our company,” Bob Rogers, Chief Executive Officer of Ivera Medical said. “It confirms our commitment to assist healthcare providers in their efforts to reduce bloodstream infections caused by touch or airborne contamination of needleless I.V. ports.”

Hospital acquired bloodstream infections dramatically increase a patient’s hospital length of stay, potential mortality and the overall cost of care, according to the Pennsylvania Health Care Cost Containment Council study. Every year in the United States alone, hospital acquired bloodstream infections are estimated to cost the healthcare system over $5 billion.

“At a time when our healthcare system is reducing reimbursements for the treatment of bloodstream infections, the Curos Port Protector will change infection control practices and help healthcare professionals improve patient care,” Jack Saladow, Vice President of Marketing and Sales for Ivera Medical said.

About Ivera Medical Corporation

Ivera Medical develops, manufactures and markets innovative, high quality medical devices to improve healthcare providers’ management and control of patient infections. Ivera Medical products are made in the USA.

www.iveramedical.com

Contact:

Ivera Medical Corporation Jack Saladow Vice President of Marketing and Sales (949) 495-7097 jsaladow@iveramedical.com

Source: Ivera Medical Corporation

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES